84.00
84.00 (0%)
As of Feb 14, 2025
Vaxcyte Inc [PCVX]
Source:
Company Overview
Vaxcyte, Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
| Country | United States |
| Headquarters | san carlos, california |
| Phone Number | ( 650 ) 837-0111 |
| Industry | manufacturing |
| CEO | Grant E. Pickering |
| Website | www.vaxcyte.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-569.5 |
| Net Income | $-463.9 |
| Net Cash | $-9.4 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -18.9% |
| Profit as % of Stockholder Equity | -14% |
Management Effectiveness
| Return on Equity | -14% |
| Return on Assets | -13.2% |
| Turnover Ratio | |
| EBITA | $-569.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $3,511.3 |
| Total Liabilities | $205.5 |
| Operating Cash Flow | $-452.6 |
| Investing Cash Flow | $-2,005.7 |
| Financing Cash Flow | $2,448.5 |
